DGHMC
KIN

Dalton, Greiner, Hartman, Maher & Co’s Kindred Biosciences, Inc. KIN Stock Holding History

Dalton, Greiner, Hartman, Maher & Co’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-141,800
Closed -$971K – 192
2019
Q3 		$971K Buy
+141,800
New +$1.04M 0.07% 158

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dalton, Greiner, Hartman, Maher & Co's KIN Position: Q4 2019 in Review

Dalton, Greiner, Hartman, Maher & Co sold out of Kindred Biosciences, Inc. (KIN) in Q4 2019, closing a stake of 141,800 shares — an estimated $971K sold.

Dalton, Greiner, Hartman, Maher & Co first reported a position in KIN in Q3 2019 and held it in 1 quarter. The position peaked at $971K in Q3 2019. 75 funds tracked by Wall St. Rank hold KIN as of Q4 2019.

  • Dalton, Greiner, Hartman, Maher & Co reported no remaining Kindred Biosciences, Inc. position as of Q4 2019 after selling out during the quarter.
  • Dalton, Greiner, Hartman, Maher & Co sold 141,800 Kindred Biosciences, Inc. shares in Q4 2019, an estimated $971K.
  • Dalton, Greiner, Hartman, Maher & Co first reported a position in Kindred Biosciences, Inc. in Q3 2019 and held it in 1 quarter.
  • Dalton, Greiner, Hartman, Maher & Co's Kindred Biosciences, Inc. position peaked at $971K in Q3 2019.
  • 75 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2019.

Based on Dalton, Greiner, Hartman, Maher & Co's 13F filing for Q4 2019, filed 15 Jan 2020.